DBDanielle L. Burke

Danielle L. Burke

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Danielle L. Burke has a total of 40 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Determining the Prevalence and Incidence of SARS-CoV-2 Infection in Prisons in England: Protocol for a Repeated Panel Survey and Enhanced Outbreak Study

    by Emma Plugge, Danielle Burke, Maciej Czachorowski, Kerry Gutridge, Fiona Maxwell, Nuala McGrath, Oscar O'MAra, Eamonn O'MOore, Julie Parkes

    Background: There are over 80,000 people imprisoned in England and Wales in 117 prisons. The management of the COVID-19 pandemic presents particular challenges in this setting where confined, crowded, and poorly ventilated conditions facilitate the rapid spread of infectious diseases. Objective: The COVID-19 in Prison Study aims to examine the epidemiology of SARS-CoV-2 in prisons in England in order to inform public health policy and practice during the pandemic and recovery. The primary objective is to estimate the proportion of positive tests of SARS-CoV-2 infection among residents and staff within selected prisons. The secondary objectives include estimating the incidence rate of SARS-CoV-2 infection and examining how the proportion of positive tests and the incidence rate vary among individual, institutional, and system level factors. Methods: Phase 1 comprises a repeated panel survey of prison residents and staff in a representative sample of 28 prisons across England. All residents and staff in the study prisons are eligible for inclusion. Participants will be tested for SARS-CoV-2 using a nasopharyngeal swab twice (6 weeks apart). Staff will also be tested for antibodies to SARS-CoV-2. Phase 2 focuses on SARS-CoV-2 infection in prisons with recognized COVID-19 outbreaks. Any prison in England will be eligible to participate if an outbreak is declared. In 3 outbreak prisons, all participating staff and residents will be tested for SARS-CoV-2 antigens at the following 3 timepoints: as soon as possible after the outbreak is declared (day 0), 7 days later (day 7), and at day 28. They will be swabbed twice (a nasal swab for lateral flow device testing and a nasopharyngeal swab for polymerase chain reaction testing). Testing will be done by external contractors. Data will also be collected on individual, prison level, and community factors. Data will be stored and handled at the University of Southampton and Public Health England. Summary statistics will summarize the prison and participant characteristics. For the primary objective, simple proportions of individuals testing positive for SARS-CoV-2 and incidence rates will be calculated. Linear regression will examine the individual, institutional, system, and community factors associated with SARS-CoV-2 infection within prisons. Results: The UK Government’s Department for Health and Social Care funds the study. Data collection started on July 20, 2020, and will end on May 31, 2021. As of May 2021, we had enrolled 4192 staff members and 6496 imprisoned people in the study. Data analysis has started, and we expect to publish the initial findings in summer/autumn 2021. The main ethical consideration is the inclusion of prisoners, who are vulnerable participants. Conclusions: This study will provide unique data to inform the public health management of SARS-CoV-2 in prisons. Its findings will be of relevance to health policy makers and practitioners working in prisons. International Registered Report Identifier (IRRID): DERR1-10.2196/30749


  • Open Access

    Determining the Prevalence and Incidence of SARS-CoV-2 Infection in Prisons in England: Protocol for a Repeated Panel Survey and Enhanced Outbreak Study (Preprint)

    by Emma Plugge, Danielle Burke, Maciej Czachorowski, Kerry Gutridge, Fiona Maxwell, Nuala McGrath, Oscar O'Mara, Eamonn O'Moore, Julie Parkes

    BACKGROUND There are over 80,000 people imprisoned in England and Wales in 117 prisons. The management of the COVID-19 pandemic presents particular challenges in this setting where confined, crowded, and poorly ventilated conditions facilitate the rapid spread of infectious diseases. OBJECTIVE The COVID-19 in Prison Study aims to examine the epidemiology of SARS-CoV-2 in prisons in England in order to inform public health policy and practice during the pandemic and recovery. The primary objective is to estimate the proportion of positive tests of SARS-CoV-2 infection among residents and staff within selected prisons. The secondary objectives include estimating the incidence rate of SARS-CoV-2 infection and examining how the proportion of positive tests and the incidence rate vary among individual, institutional, and system level factors. METHODS Phase 1 comprises a repeated panel survey of prison residents and staff in a representative sample of 28 prisons across England. All residents and staff in the study prisons are eligible for inclusion. Participants will be tested for SARS-CoV-2 using a nasopharyngeal swab twice (6 weeks apart). Staff will also be tested for antibodies to SARS-CoV-2. Phase 2 focuses on SARS-CoV-2 infection in prisons with recognized COVID-19 outbreaks. Any prison in England will be eligible to participate if an outbreak is declared. In 3 outbreak prisons, all participating staff and residents will be tested for SARS-CoV-2 antigens at the following 3 timepoints: as soon as possible after the outbreak is declared (day 0), 7 days later (day 7), and at day 28. They will be swabbed twice (a nasal swab for lateral flow device testing and a nasopharyngeal swab for polymerase chain reaction testing). Testing will be done by external contractors. Data will also be collected on individual, prison level, and community factors. Data will be stored and handled at the University of Southampton and Public Health England. Summary statistics will summarize the prison and participant characteristics. For the primary objective, simple proportions of individuals testing positive for SARS-CoV-2 and incidence rates will be calculated. Linear regression will examine the individual, institutional, system, and community factors associated with SARS-CoV-2 infection within prisons. RESULTS The UK Government’s Department for Health and Social Care funds the study. Data collection started on July 20, 2020, and will end on May 31, 2021. As of May 2021, we had enrolled 4192 staff members and 6496 imprisoned people in the study. Data analysis has started, and we expect to publish the initial findings in summer/autumn 2021. The main ethical consideration is the inclusion of prisoners, who are vulnerable participants. CONCLUSIONS This study will provide unique data to inform the public health management of SARS-CoV-2 in prisons. Its findings will be of relevance to health policy makers and practitioners working in prisons. INTERNATIONAL REGISTERED REPORT DERR1-10.2196/30749

  • Open Access

    One‐stage individual participant data meta‐analysis models for continuous and binary outcomes: Comparison of treatment coding options and estimation methods

    by Richard D. Riley, Amardeep Legha, Dan Jackson, Tim P. Morris, Joie Ensor, Kym I.E. Snell, Ian R. White, Danielle L. Burke

    A one‐stage individual participant data (IPD) meta‐analysis synthesizes IPD from multiple studies using a general or generalized linear mixed model. This produces summary results (eg, about treatment effect) in a single step, whilst accounting for clustering of participants within studies (via a stratified study intercept, or random study intercepts) and between‐study heterogeneity (via random treatment effects). We use simulation to evaluate the performance of restricted maximum likelihood (REML) and maximum likelihood (ML) estimation of one‐stage IPD meta‐analysis models for synthesizing randomized trials with continuous or binary outcomes. Three key findings are identified. First, for ML or REML estimation of stratified intercept or random intercepts models, a t‐distribution based approach generally improves coverage of confidence intervals for the summary treatment effect, compared with a z‐based approach. Second, when using ML estimation of a one‐stage model with a stratified intercept, the treatment variable should be coded using “study‐specific centering” (ie, 1/0 minus the study‐specific proportion of participants in the treatment group), as this reduces the bias in the between‐study variance estimate (compared with 1/0 and other coding options). Third, REML estimation reduces downward bias in between‐study variance estimates compared with ML estimation, and does not depend on the treatment variable coding; for binary outcomes, this requires REML estimation of the pseudo‐likelihood, although this may not be stable in some situations (eg, when data are sparse). Two applied examples are used to illustrate the findings.


  • Top Cited Papers
    Open Access

    Minimum sample size for developing a multivariable prediction model: PART II ‐ binary and time‐to‐event outcomes

    by Richard D Riley, Kym Ie Snell, Joie Ensor, Danielle L Burke, Frank E Harrell Jr, Karel Gm Moons, Gary S Collins

    When designing a study to develop a new prediction model with binary or time‐to‐event outcomes, researchers should ensure their sample size is adequate in terms of the number of participants (n) and outcome events (E) relative to the number of predictor parameters (p) considered for inclusion. We propose that the minimum values ofnandE(and subsequently the minimum number of events per predictor parameter, EPP) should be calculated to meet the following three criteria: (i) small optimism in predictor effect estimates as defined by a global shrinkage factor of≥0.9, (ii) small absolute difference of≤0.05 in the model's apparent and adjusted Nagelkerke'sR2, and (iii) precise estimation of the overall risk in the population. Criteria (i) and (ii) aim to reduce overfitting conditional on a chosenp, and require prespecification of the model's anticipated Cox‐SnellR2, which we show can be obtained from previous studies. The values ofnandEthat meet all three criteria provides the minimum sample size required for model development. Upon application of our approach, a new diagnostic model for Chagas disease requires an EPP of at least 4.8 and a new prognostic model for recurrent venous thromboembolism requires an EPP of at least 23. This reinforces why rules of thumb (eg, 10 EPP) should be avoided. Researchers might additionally ensure the sample size gives precise estimates of key predictor effects; this is especially important when key categorical predictors have few events in some categories, as this may substantially increase the numbers required.


  • Top Cited Papers

    Minimum sample size for developing a multivariable prediction model: Part I – Continuous outcomes

    by Richard D. Riley, Kym I.E. Snell, Joie Ensor, Danielle L. Burke, Frank E. Harrell, Karel G.M. Moons, Gary S. Collins

    In the medical literature, hundreds of prediction models are being developed to predict health outcomes in individuals. For continuous outcomes, typically a linear regression model is developed to predict an individual's outcome value conditional on values of multiple predictors (covariates). To improve model development and reduce the potential for overfitting, a suitable sample size is required in terms of the number of subjects (n) relative to the number of predictor parameters (p) for potential inclusion. We propose that the minimum value ofnshould meet the following four key criteria: (i) small optimism in predictor effect estimates as defined by a global shrinkage factor of≥0.9; (ii) small absolute difference of≤0.05 in the apparent and adjustedR2; (iii) precise estimation (a margin of error≤10% of the true value) of the model's residual standard deviation; and similarly, (iv) precise estimation of the mean predicted outcome value (model intercept). The criteria require prespecification of the user's chosenpand the model's anticipatedR2as informed by previous studies. The value ofnthat meets all four criteria provides the minimum sample size required for model development. In an applied example, a new model to predict lung function in African‐American women using 25 predictor parameters requires at least 918 subjects to meet all criteria, corresponding to at least 36.7 subjects per predictor parameter. Even larger sample sizes may be needed to additionally ensure precise estimates of key predictor effects, especially when important categorical predictors have low prevalence in certain categories.


  • Open Access

    Individual participant data meta‐analysis of continuous outcomes: A comparison of approaches for specifying and estimating one‐stage models

    by Amardeep Legha, Richard D. Riley, Joie Ensor, Kym I.E. Snell, Tim P. Morris, Danielle L. Burke

    One‐stage individual participant data meta‐analysis models should account for within‐trial clustering, but it is currently debated how to do this. For continuous outcomes modeled using a linear regression framework, two competing approaches are a stratified intercept or a random intercept. The stratified approach involves estimating a separate intercept term for each trial, whereas the random intercept approach assumes that trial intercepts are drawn from a normal distribution. Here, through an extensive simulation study for continuous outcomes, we evaluate the impact of using the stratified and random intercept approaches on statistical properties of the summary treatment effect estimate. Further aims are to compare (i) competing estimation options for the one‐stage models, including maximum likelihood and restricted maximum likelihood, and (ii) competing options for deriving confidence intervals (CI) for the summary treatment effect, including the standard normal‐based 95% CI, and more conservative approaches of Kenward‐Roger and Satterthwaite, which inflate CIs to account for uncertainty in variance estimates. The findings reveal that, for an individual participant data meta‐analysis of randomized trials with a 1:1 treatment:control allocation ratio and heterogeneity in the treatment effect, (i) bias and coverage of the summary treatment effect estimate are very similar when using stratified or random intercept models with restricted maximum likelihood, and thus either approach could be taken in practice, (ii) CIs are generally best derived using either a Kenward‐Roger or Satterthwaite correction, although occasionally overly conservative, and (iii) if maximum likelihood is required, a random intercept performs better than a stratified intercept model. An illustrative example is provided.


  • Guidance for deriving and presenting percentage study weights in meta‐analysis of test accuracy studies

    by Danielle L. Burke, Joie Ensor, Kym I.E. Snell, Danielle van der Windt, Richard D. Riley

    Percentage study weights in meta‐analysis reveal the contribution of each study toward the overall summary results and are especially important when some studies are considered outliers or at high risk of bias. In meta‐analyses of test accuracy reviews, such as a bivariate meta‐analysis of sensitivity and specificity, the percentage study weights are not currently derived. Rather, the focus is on representing the precision of study estimates on receiver operating characteristic plots by scaling the points relative to the study sample size or to their standard error. In this article, we recommend that researchers should also provide the percentage study weights directly, and we propose a method to derive them based on a decomposition of Fisher information matrix. This method also generalises to a bivariate meta‐regression so that percentage study weights can also be derived for estimates of study‐level modifiers of test accuracy. Application is made to two meta‐analyses examining test accuracy: one of ear temperature for diagnosis of fever in children and the other of positron emission tomography for diagnosis of Alzheimer's disease. These highlight that the percentage study weights provide important information that is otherwise hidden if the presentation only focuses on precision based on sample size or standard errors. Software code is provided for Stata, and we suggest that our proposed percentage weights should be routinely added on forest and receiver operating characteristic plots for sensitivity and specificity, to provide transparency of the contribution of each study toward the results. This has implications for the PRISMA–diagnostic test accuracy guidelines that are currently being produced.


  • Open Access

    Perioperative supplementation with a fruit and vegetable juice powder concentrate and postsurgical morbidity: A double-blind, randomised, placebo-controlled clinical trial

    by Patricia Gorecki, Danielle L. Burke, Iain L.C. Chapple, Karla Hemming, Daniel Saund, David Pearson, Wilhelm Stahl, Ryan Lello, Thomas Dietrich


  • Association of maternal serum PAPP‐A levels, nuchal translucency and crown–rump length in first trimester with adverse pregnancy outcomes: retrospective cohort study

    by Ashwini Bilagi, Danielle L. Burke, Richard D. Riley, Ian Mills, Mark D. Kilby, R. Katie Morris

    What's already known about this topic? Low levels of PAPP‐A are associated with small for gestational age and PE. What does this study adds? NT, CRL and PAPP‐A are independent prognostic markers for adverse pregnancy outcome. Further work is required to assess the predictive ability of these factors in prediction models. © 2017 John Wiley & Sons, Ltd.


  • Open Access

    Deriving percentage study weights in multi-parameter meta-analysis models: with application to meta-regression, network meta-analysis and one-stage individual participant data models

    by Richard D Riley, Joie Ensor, Dan Jackson, Danielle L Burke

    Many meta-analysis models contain multiple parameters, for example due to multiple outcomes, multiple treatments or multiple regression coefficients. In particular, meta-regression models may contain multiple study-level covariates, and one-stage individual participant data meta-analysis models may contain multiple patient-level covariates and interactions. Here, we propose how to derive percentage study weights for such situations, in order to reveal the (otherwise hidden) contribution of each study toward the parameter estimates of interest. We assume that studies are independent, and utilise a decomposition of Fisher’s information matrix to decompose the total variance matrix of parameter estimates into study-specific contributions, from which percentage weights are derived. This approach generalises how percentage weights are calculated in a traditional, single parameter meta-analysis model. Application is made to one- and two-stage individual participant data meta-analyses, meta-regression and network (multivariate) meta-analysis of multiple treatments. These reveal percentage study weights toward clinically important estimates, such as summary treatment effects and treatment-covariate interactions, and are especially useful when some studies are potential outliers or at high risk of bias. We also derive percentage study weights toward methodologically interesting measures, such as the magnitude of ecological bias (difference between within-study and across-study associations) and the amount of inconsistency (difference between direct and indirect evidence in a network meta-analysis).